OTCMKTS:IGXT IntelGenx Technologies (IGXT) Stock Price, News & Analysis $0.17 0.00 (0.00%) As of 07/13/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About IntelGenx Technologies Stock (OTCMKTS:IGXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IntelGenx Technologies alerts:Sign Up Key Stats Today's Range$0.17▼$0.1750-Day Range$0.17▼$0.1752-Week Range$0.09▼$0.22VolumeN/AAverage VolumeN/AMarket Capitalization$29.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview IntelGenx Technologies Inc. is a specialty pharmaceutical company headquartered in Montreal, Canada, that focuses on the development and commercialization of novel drug delivery systems. Established to address limitations of traditional oral and injectable formulations, the company’s technology platforms aim to improve patient compliance, enhance bioavailability and provide controlled release profiles for a variety of therapeutic agents. The core of IntelGenx’s offering lies in its proprietary film-based delivery technologies, including RapidFilm and MucoFilm, which are thin polymer films designed for oral mucosal administration. These films can dissolve quickly or be formulated for sustained release, enabling delivery of small molecules, peptides and other active pharmaceutical ingredients without the need for water or swallowing. In addition, the company is advancing its ProNeura long-acting drug delivery system, an implantable rod designed for sustained release over periods of months to years, with potential applications in chronic disease and hormone therapies. IntelGenx collaborates with pharmaceutical partners around the world to in-license development candidates and out-license its delivery platforms for late-stage clinical or commercial programs. With strategic alliances spanning North America, Europe and other regions, the company seeks to leverage its manufacturing facility in Cowansville, Québec, to support both clinical supply and commercial production. Led by a management team with extensive experience in formulation science and pharmaceutical product development, IntelGenx continues to advance a pipeline of programs aimed at addressing unmet medical needs and improving patient outcomes.AI Generated. May Contain Errors. Read More Receive IGXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IGXT Stock News HeadlinesIntelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News SummaryAugust 18, 2024 | benzinga.comIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 20, 2024 | finanznachrichten.deRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.July 14 at 1:00 AM | Porter & Company (Ad)IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 19, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJuly 3, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessJune 11, 2024 | globenewswire.comIntelGenx Obtains Court-Approval of a Sale and Investment Solicitation ProcessMay 28, 2024 | globenewswire.comIntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic AlternativesMay 17, 2024 | globenewswire.comSee More Headlines IGXT Stock Analysis - Frequently Asked Questions How have IGXT shares performed this year? IntelGenx Technologies' stock was trading at $0.1670 on January 1st, 2026. Since then, IGXT shares have increased by 0.0% and is now trading at $0.1670. How were IntelGenx Technologies' earnings last quarter? IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01. The company earned $0.51 million during the quarter. How do I buy shares of IntelGenx Technologies? Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IntelGenx Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Pfizer (PFE), Tesla (TSLA), Advanced Micro Devices (AMD), Ford Motor (F), Rithm Capital (RITM), Rolls-Royce Holdings PLC (RYCEY) and Blink Charging (BLNK). Company Calendar Last Earnings11/12/2020Today7/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IGXT CIK1098880 Webwww.intelgenx.com Phone(514) 331-7440Fax514-331-0436Employees38Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.04 million Price / Sales28.05 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-2.39Miscellaneous Outstanding Shares174,658,000Free Float101,214,000Market Cap$29.17 million OptionableNot Optionable Beta2.47 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:IGXT) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersWhen I found Rolls-Royce under $2, most people thought I was crazyIn 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...Monument Traders Alliance | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | Sponsored1 Stock to Own by July 31stA scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...Chaikin Analytics | SponsoredTrump Set to Unleash 219-Year-Old “Super Weapon” on U.S. SoilFour-time U.S. Presidential advisor Jim Rickards is warning of a political move he calls 'The Trump Supremacy'...Paradigm Press | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IntelGenx Technologies Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IntelGenx Technologies With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
